Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Safety and Efficacy of MK-8457 and Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Despite MTX Therapy (P08683, MK-8457-008)

18 de marzo de 2019 actualizado por: Merck Sharp & Dohme LLC

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Worldwide, Dose-Ranging Clinical Trial With a Proof-of-Concept Lead Cohort to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 + MTX in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

The purpose of this study is to assess the safety and efficacy of MK-8457 + Methotrexate (MTX) in participants with active rheumatoid arthritis (RA) despite MTX therapy. The primary hypothesis is that at least 1 dose of MK-8457 + MTX will be superior to placebo + MTX as measured by the percentage of participants who achieve American College of Rheumatology 20 (ACR 20) response after 12 weeks of treatment.

Descripción general del estudio

Estado

Terminado

Condiciones

Intervención / Tratamiento

Descripción detallada

In Base Study Phase IIa, participants were to receive blinded MK-8457 100 mg or matched placebo for up to 24 weeks. At Week 12 and 18 of Phase IIa, efficacy evaluation was conducted to assess eligibility for early escape, defined as <20% reduction in both tender and swollen joint counts. The study plan included Base Study Phase IIb in which dose range finding or dose-response was to be evaluated, depending on the outcome of Phase IIa. Participants who completed Phase IIa or Phase IIb and those eligible for early escape could enroll in Period 3, a 2-year Safety Extension.

All participants must have been treated with MTX for at least 3 months prior to screening and have been receiving a stable dose of MTX for at least 4 weeks prior to screening.

Tipo de estudio

Intervencionista

Inscripción (Actual)

82

Fase

  • Fase 2

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Diagnosis of rheumatoid arthritis for at least 6 months prior to screening
  • Active rheumatoid arthritis as defined by the presence of >= 6 swollen joints (of 66 count) and >= 6 tender joints (of 68 joint count)
  • C-reactive protein blood level >0.9 mg/dL
  • Anti-citrullinated protein antibody positive and/or rheumatoid factor positive at screening
  • American College of Rheumatology Functional Class I, II, or III
  • Received methotrexate for a minimum of 3 months prior to screening with a regionally appropriate stable weekly dose for at least 4 weeks prior to screening
  • If using oral corticosteroids, the participant must be on a stable dose of 10 mg prednisone
  • No history of either untreated, latent, or active tuberculosis prior to baseline
  • Participants of reproductive potential must agree to remain abstinent or use 2 acceptable methods of birth control

Exclusion Criteria:

  • Presence of inflammatory disease other than rheumatoid arthritis, including but not limited to psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus, or Lyme disease
  • Positive hepatitis B surface antigen or hepatitis C test result or the presence of Human immunodeficiency virus (HIV) infection
  • HIV positive
  • User of recreational or illicit drugs or has had a history (within the previous 2 years) of drug or alcohol abuse or dependence
  • Females of childbearing potential who are pregnant, intend to become pregnant, or are lactating;
  • Severe opportunistic infection within 6 months prior to study start.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Base Study Phase IIa: MK-8457
Participants received MK-8457 100 mg dosed twice daily (BID) orally with MTX at the stable dose received upon study enrollment. Phase IIa lasted up to 24 weeks.
Droga: MK-8457 100 mg
MK-8457 100 mg dosificados por vía oral BID
Droga: Methotrexate
MTX dosed at the stable dose receive upon study entry
Otros nombres:
  • MTX
Comparador de placebos: Base Study Phase IIa: Placebo
Participants received placebo dosed BID orally with MTX at the stable dose received upon study enrollment. Phase IIa lasted up to 24 weeks.
Droga: Methotrexate
MTX dosed at the stable dose receive upon study entry
Otros nombres:
  • MTX
Droga: Dose-Matched Placebo
Dose-matched placebo dosed orally BID
Experimental: Safety Extension Period 3: MK-8457
Participants received MK-8457 100 mg BID orally with MTX at the stable dose received upon study enrollment. Period 3 was to last up to 2 years.
Droga: MK-8457 100 mg
MK-8457 100 mg dosificados por vía oral BID
Droga: Methotrexate
MTX dosed at the stable dose receive upon study entry
Otros nombres:
  • MTX

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Porcentaje de participantes que lograron una respuesta del American College of Rheumatology (ACR) 20 en la semana 12
Periodo de tiempo: Semana 12
Las respuestas ACR son medidas numéricas de mejora en múltiples criterios de evaluación de enfermedades. Una respuesta ACR20 se define como una mejora de ≥20 % en 1) recuento de articulaciones inflamadas (66 articulaciones) y recuento de articulaciones dolorosas (68 articulaciones) (0 = Ausente; 1 = Presente) y 2) ≥20 % de mejora en 3 de los siguientes 5 evaluaciones: a) la evaluación general del dolor de un participante en una escala analógica visual (VAS, sin dolor = 0 a dolor extremo = 100); b) Evaluación global de la actividad de la enfermedad del paciente EVA (muy bien = 0 a muy mal = 100); c) Evaluación global de la actividad de la enfermedad del investigador VAS (muy bien = 0 a muy mal = 100; d) evaluación de la función del participante en 8 áreas funcionales según lo medido por el Cuestionario de evaluación de la salud (HAQ), puntajes totales que van desde ninguna dificultad = 0 a incapacidad para realizar tareas =24; ye) proteína C reactiva sérica (la disminución indica una mejora). Esta medida de resultado se aplicó únicamente a los participantes del Estudio Base.
Semana 12

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change From Baseline in Disease Activity Score (DAS28) as Measured by Erythrocyte Sedimentation Rate (ESR) at Week 12
Periodo de tiempo: Baseline and Week 12
The DAS28-ESR is a continuous parameter based upon a statistically-derived index combining tender joints (28 joints, TEN28), swollen joints (28 joints, SW28), ESR (an inflammatory marker), and Patient's Global Assessment of Disease Activity VAS (GH). It is defined as follows: DAS28-ESR = 0.56 × SQRT(TEN28) + 0.28 × SQRT(SW28) + 0.70 × ln (ESR) + 0.014 × GH. SQRT = square root. The DAS28-ESR is a scale ranging from 0 to 10 with higher values indicating greater rheumatoid arthritis (RA) disease activity. This outcome measure applied to Base Study participants only.
Baseline and Week 12
Change From Baseline in DAS28 as Measured by C-Reactive Protein (CRP) at Week 12
Periodo de tiempo: Baseline and Week 12
The DAS28-CRP is a continuous parameter based upon a statistically-derived index combining tender joints (28 joints, TEN28), swollen joints (28 joints, SW28), CRP (an inflammatory marker), and Patient's Global Assessment of Disease Activity VAS (GH). It is defined as follows: DAS28-CRP = 0.56 × SQRT(TEN28) + 0.28 × SQRT(SW28) + 0.36 × ln (CRP+1) + 0.014 × GH + 0.96. The DAS28-CRP is a scale ranging from 0 to 10 with higher values indicating greater RA disease activity. This outcome measure applied to Base Study participants only.
Baseline and Week 12
Percentage of Participants Achieving an ACR70 Response at Week 12
Periodo de tiempo: Week 12
ACR responses are numerical measurements of improvement in multiple disease assessment criteria. An ACR70 response is defined as a ≥70% improvement in 1) swollen joint count (66 joints) and tender joint count (68 joints) (0 = Absent; 1 = Present) and 2) ≥70% improvement in 3 of the following 5 assessments: a) a participant's overall assessment of pain on a visual analog scale (VAS, no pain =0 to extreme pain =100); b) Patient's Global Assessment of Disease Activity VAS (doing very well =0 to doing very poor =100); c) Investigator's Global Assessment of Disease Activity VAS (doing very well =0 to doing very poor =100 ; d) participant's assessment of function across 8 functional areas as measured by Health Assessment Questionnaire (HAQ), total scores ranging from no difficulty =0 to inability to perform tasks =24; and e) serum C-Reactive Protein (decrease indicates improvement). This outcome measure applied to Base Study participants only.
Week 12
Percentage of Participants Achieving Hybrid ACR Response at Week 12
Periodo de tiempo: Week 12
Hybrid ACR Response evaluates the improvement in active RA by combining elements of the ACR20/50/70 with a categorical score of the mean change in the core set measures (tender joint count, swollen joint count, Patient's Global Assessment of Disease Activity, Investigator's Global Assessment of Disease Activity, disability index of the HAQ, and CRP). The mean percentage improvement from Baseline in the core set measures was computed and used with the participant's ACR20, ACR50, and ACR70 status to determine the hybrid ACR response in a lookup table. The range of values was -100 to 100, with a positive change indicating improvement. This outcome measure applied to Base Study participants only.
Week 12
Percentage of Participants Achieving an ACR-N Response at Week 12
Periodo de tiempo: Week 12
The ACR-N response is the minimum of the following: 1) the percent decrease from Baseline in tender joint counts (68 joints, 0 = absent, 1 = present); 2) the percent decrease from Baseline in swollen joint counts (66 joints, 0 = absent, 1 = present); and 3) the median percent decrease from Baseline for the following: a) Patient's Global Assessment of Pain (VAS, 0 mm = "no pain" and 100 mm = "extreme pain"); b) Patient's Global Assessment of Disease Activity (VAS, 0 mm = doing very well to 100 mm = doing very poor); c) Investigator's Global Assessment of Disease Activity (VAS, 0 mm = doing very well to 100 mm = doing very poor); d. physical function as measured by the HAQ (Likert scale, 0 to 3 with a lower score indicating less disability); and e) CRP. This outcome measure applied to Base Study participants only.
Week 12
Percentage of Participants Achieving a DAS28-ESR Response at Week 12
Periodo de tiempo: Week 12
The DAS28-ESR is a continuous parameter based upon a statistically-derived index combining tender joints (28 joints, TEN28), swollen joints (28 joints, SW28), ESR, and Patient's Global Assessment of Disease Activity VAS (GH). It is defined as follows: DAS28-ESR = 0.56 × SQRT(TEN28) + 0.28 × SQRT(SW28) + 0.70 × ln (ESR) + 0.014 × GH. SQRT = square root. The DAS28-ESR is a scale ranging from 0 to 10 with higher values indicating greater RA disease activity. Depending upon the DAS28-ESR value for a given visit, change in DAS28-ESR is categorized as follows: No Response (reduction from Baseline ≤0.6), No response or Moderate Response (reduction >0.6 - 1.2), and Moderate or Good Response (reduction >1.2). The percentage of participants with a Moderate or Good change in DAS28-ESR was reported. This outcome measure applied to Base Study participants only.
Week 12
Percentage of Participants Achieving a DAS28-CRP Response at Week 12
Periodo de tiempo: Week 12
The DAS28-CRP is a continuous parameter based upon a statistically-derived index combining tender joints (28 joints, TEN28), swollen joints (28 joints, SW28), CRP, and Patient's Global Assessment of Disease Activity VAS (GH). It is defined as follows: DAS28-CRP = 0.56 × SQRT(TEN28) + 0.28 × SQRT(SW28) + 0.36 × ln (CRP+1) + 0.014 × GH + 0.96. The DAS28-CRP is a scale ranging from 0 to 10 with higher values indicating greater RA disease activity. Depending upon the DAS28-CRP value for a given visit, change in DAS28-CRP is categorized as follows: No Response (reduction from Baseline ≤0.6), No response or Moderate Response (reduction >0.6 - 1.2), and Moderate or Good Response (reduction >1.2). The percentage of participants with a Moderate or Good change in DAS28-CRP was reported. This outcome measure applied to Base Study participants only.
Week 12
Percentage of Participants Achieving DAS28-ESR Remission at Week 12
Periodo de tiempo: Week 12
The DAS28-ESR is a continuous parameter based upon a statistically-derived index combining tender joints (28 joints, TEN28), swollen joints (28 joints, SW28), ESR, and Patient's Global Assessment of Disease Activity VAS (GH). It is defined as follows: DAS28-ESR = 0.56 × SQRT(TEN28) + 0.28 × SQRT(SW28) + 0.70 × ln (ESR) + 0.014 × GH. SQRT = square root. The DAS28-ESR is a scale ranging from 0 to 10 with higher values indicating greater RA disease activity. DAS28-ESR remission is defined as a value <2.6 at the visit. This outcome measure applied to Base Study participants only.
Week 12
Percentage of Participants Achieving DAS28-CRP Remission at Week 12
Periodo de tiempo: Week 12
The DAS28-CRP is a continuous parameter derived from the formula: 0.56 × the square root of the tender joint count (0-28) + 0.28 × the square root of the swelling joint count (0-28) + 0.36 × the C reactive protein value (in mg/L +1) + 0.014 × Patient's Global Assessment of Disease Activity VAS of 0-100 mm + 0.96. The DAS28-CRP is a scale ranging from 0 to 10 with higher values indicating greater RA disease activity. DAS28-CRP remission is defined as a value <2.6 at the visit. This outcome measure applied to Base Study participants only.
Week 12
DAS28-ESR Area Under the Curve (AUC)
Periodo de tiempo: Up to 12 weeks
DAS28-ESR AUC was to be calculated from the DAS28-ESR score versus time curve, which provided an assessment of changes in disease activity over time. The DAS28-ESR AUC was to be calculated using the trapezoidal rule as the DAS28-ESR multiplied by the duration of the assessment period (in weeks) and was to be expressed as %-weeks. A higher calculated AUC value indicates higher disease activity (worse). This outcome measure applied to Base Study participants only.
Up to 12 weeks
DAS28-CRP Area Under the Curve (AUC)
Periodo de tiempo: Up to 12 weeks
DAS28-CRP AUC was to be calculated from the DAS28-CRP score versus time curve, which provided an assessment of changes in disease activity over time. The DAS28-CRP AUC was to be calculated using the trapezoidal rule as the DAS28-CRP multiplied by the duration of the assessment period (in weeks) and was to be expressed as %-weeks. A higher calculated AUC value indicates higher disease activity (worse). This outcome measure applied to Base Study participants only.
Up to 12 weeks
Change From Baseline in Tender Joint Count at Week 12
Periodo de tiempo: Baseline and Week 12
Tender Joint Count was examined on 68 joints of the fingers, elbows, hips, knees, ankles, and toes distal for pain in response to pressure or passive motion at the study time points. Joint pain was scored as 0 = Absent; 1 = Present for each joint. The overall Tender Joint Count ranged from 0 to 68. A higher score indicated greater disease severity. This outcome measure applied to Base Study participants only.
Baseline and Week 12
Change From Baseline in Swollen Joint Count at Week 12
Periodo de tiempo: Baseline and Week 12
Swollen joint count included 66 joints (same joints as for tender joint count except this excluded evaluation of hips) that were assessed for the presence of swelling. Soft tissue swelling was considered to be present if there was palpable or visible evidence of capsular distention considered to be due to either synovial thickening and/or a joint effusion. Bony swelling, nodule formation, and joint deformity were excluded from consideration. A swollen joint was scored as 0 = Absent; 1 = Present for each joint. The overall swollen joint count ranged from 0 to 66. A higher score indicated greater disease severity. This outcome measure applied to Base Study participants only.
Baseline and Week 12
Change From Baseline in the Simplified Disease Activity Index (SDAI) at Week 12
Periodo de tiempo: Baseline and Week 12
SDAI is the simple linear sum of the following parameters: tender joint count (TJC) and swollen joint count (SJC) based on a 28-joint assessment, Patient's Global Assessment of Disease Activity [PGA, VAS 0 to 10 cm], Investigator's Global Assessment of Disease Activity (MDGA, VAS 0 to 10 cm) and CRP levels (mg/dL). SDAI =TJC + SJC + PGA + MDGA + CRP. Overall scores can range from 0.0 to 86.0. A higher score indicated greater disease severity. This outcome measure applied to Base Study participants only.
Baseline and Week 12
Change From Baseline in the Short Form Health Survey (SF-36) at Week 12
Periodo de tiempo: Baseline and Week 12
The SF-36 is a health-related quality of life instrument that consists of 8 multi-item scales: limitations in physical functioning due to health problems, limitations in usual role activities due to physical health problems, bodily pain, general mental health (psychological distress and well-being), limitations in usual role activities due to personal or emotional problems, limitations in social functioning due to physical or mental health problems, vitality (energy and fatigue), and general health perception. Each scale is directly transformed into a 0 to 100 scale on the assumption that each question carries equal weight. The lower the score the greater the disability i.e., a score of 0 corresponds to maximum disability and a score of 100 corresponds to no disability. This outcome measure applied to Base Study participants only.
Baseline and Week 12
Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at Week 12
Periodo de tiempo: Baseline and Week 12
The FACIT-F is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). The higher the participant's response to the questions the greater the participant's fatigue. This outcome measure applied to Base Study participants only.
Baseline and Week 12
Change From Baseline in the Patient's Global Assessment of Disease Status/Activity (PGADSA) at Week 12
Periodo de tiempo: Baseline and Week 12
A participant's overall assessment of pain was assessed from the amount of pain due to arthritis experienced during the past 48 hours on a VAS, where 0 mm = doing very well to 100 mm = doing very poor. A negative change from Baseline indicates improvement. This outcome measure applied to Base Study participants only.
Baseline and Week 12
Change From Baseline in the Investigator's Global Assessment of Disease Status/Activity (IGADSA) at Week 12
Periodo de tiempo: Baseline and Week 12
The Investigator's Global Assessment of Disease Status/Activity (IGADSA) is measured with scores ranging from 0 to 100 mm (VAS, 0 mm = doing very well to 100 mm = doing very poor). A negative change from Baseline indicates improvement. This outcome measure applied to Base Study participants only.
Baseline and Week 12
Change From Baseline in the Patient's Global Assessment of Pain (PGAP) at Week 12
Periodo de tiempo: Baseline and Week 12
A participant's overall assessment of pain was assessed from the amount of pain due to arthritis experienced during the past 48 hours on a VAS where 0 mm = "no pain" and 100 mm = "extreme pain". A negative change from Baseline indicates improvement. This outcome measure applied to Base Study participants only.
Baseline and Week 12
Cambio desde el inicio en la discapacidad del cuestionario de evaluación de la salud (índice de discapacidad HAQ) en la semana 12
Periodo de tiempo: Línea de base y semana 12
El estado funcional del participante se evaluó mediante el Índice de Discapacidad del HAQ en una escala de Likert. Este instrumento de 20 preguntas evalúa el grado de dificultad que tiene una persona para realizar tareas en 8 áreas funcionales (vestirse, levantarse, comer, caminar, higiene, alcanzar, agarrar y actividades de la vida diaria). Las respuestas en cada área funcional se califican de 0, que indica que no hay dificultad, a 3, que indica incapacidad para realizar una tarea en esa área. La puntuación general del Índice de discapacidad es la media de las 8 puntuaciones de las áreas funcionales y también varía de 0 a 3, donde una puntuación más baja indica menos discapacidad. Un cambio negativo desde la línea de base indica una mejora. Esta medida de resultado se aplicó únicamente a los participantes del Estudio Base.
Línea de base y semana 12
Change From Baseline in Serum C-Reactive Protein (CRP) at Week 12
Periodo de tiempo: Baseline and Week 12
C-Reactive Protein is an inflammatory marker with a normal reference range of less than 0.9 mg/dL. Change from Baseline in CRP at Week 12 (Week 12 concentration minus Baseline concentration). This outcome measure applied to Base Study participants only.
Baseline and Week 12
Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Week 12
Periodo de tiempo: Baseline and Week 12
The ESR is the rate at which red blood cells sediment in a period of one hour, and is a non-specific measure of inflammation. Change from Baseline is ESR at Week 12 minus ESR at Baseline. This outcome measure applied to Base Study participants only.
Baseline and Week 12
Change From Baseline in Hemoglobin at Week 12
Periodo de tiempo: Baseline and Week 12
Hemoglobin is the iron-containing oxygen-transport metalloprotein in red blood cells. Change from Baseline is hemoglobin at Week 12 minus hemoglobin at Baseline. This outcome measure applied to Base Study participants only.
Baseline and Week 12
Porcentaje de participantes que lograron una respuesta ACR50 en la semana 12
Periodo de tiempo: Semana 12
Las respuestas ACR son medidas numéricas de mejora en múltiples criterios de evaluación de enfermedades. Una respuesta ACR50 se define como una mejora ≥50 % en 1) recuento de articulaciones inflamadas (66 articulaciones) y recuento de articulaciones sensibles (68 articulaciones) (0 = Ausente; 1 = Presente) y 2) ≥50 % de mejora en 3 de los siguientes 5 evaluaciones: a) la evaluación general del dolor de un participante en una escala analógica visual (VAS, sin dolor = 0 a dolor extremo = 100); b) Evaluación global de la actividad de la enfermedad del paciente EVA (muy bien = 0 a muy mal = 100); c) Evaluación global de la actividad de la enfermedad del investigador VAS (muy bien = 0 a muy mal = 100; d) evaluación de la función del participante en 8 áreas funcionales según lo medido por el Cuestionario de evaluación de la salud (HAQ), puntajes totales que van desde ninguna dificultad = 0 a incapacidad para realizar tareas =24; ye) proteína C reactiva sérica (la disminución indica una mejora). Esta medida de resultado se aplicó únicamente a los participantes del Estudio Base.
Semana 12
Percentage of Participants With an ACR20 Response Over Time
Periodo de tiempo: Week 1, Week 2, Week 4, Week 6, Week 18 and Week 24
ACR responses are numerical measurements of improvement in multiple disease assessment criteria. An ACR20 response is defined as a ≥20% improvement in 1) swollen joint count (66 joints) and tender joint count (68 joints) (0 = Absent; 1 = Present) and 2) ≥20% improvement in 3 of the following 5 assessments: a) a participant's overall assessment of pain on a visual analog scale (VAS, no pain =0 to extreme pain =100); b) Patient's Global Assessment of Disease Activity VAS (doing very well =0 to doing very poor =100); c) Investigator's Global Assessment of Disease Activity VAS (doing very well =0 to doing very poor =100 ; d) participant's assessment of function across 8 functional areas as measured by Health Assessment Questionnaire (HAQ), total scores ranging from no difficulty =0 to inability to perform tasks =24; and e) serum C-Reactive Protein (decrease indicates improvement). This outcome measure applied to Base Study participants only.
Week 1, Week 2, Week 4, Week 6, Week 18 and Week 24

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Merck Sharp & Dohme LLC

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

22 de mayo de 2012

Finalización primaria (Actual)

3 de octubre de 2013

Finalización del estudio (Actual)

3 de octubre de 2013

Fechas de registro del estudio

Enviado por primera vez

30 de marzo de 2012

Primero enviado que cumplió con los criterios de control de calidad

30 de marzo de 2012

Publicado por primera vez (Estimar)

2 de abril de 2012

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

27 de marzo de 2019

Última actualización enviada que cumplió con los criterios de control de calidad

18 de marzo de 2019

Última verificación

1 de marzo de 2019

Más información

Términos relacionados con este estudio

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • P08683 (Otro identificador: Merck)
  • MK-8457-008 (Otro identificador: Merck)
  • 2012-000439-17 (Número EudraCT)
  • 132235 (Identificador de registro: JAPIC-CTI)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

Sí

Descripción del plan IPD

http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Ensayos clínicos sobre Artritis reumatoide (AR)

Ensayos clínicos sobre MK-8457 100 mg

Buscar ensayos similares

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

CROs by country

CROs in Gambia

Condiciones

Enfermedades Raras

Intervenciones de drogas

Suplementos dietéticos

Patrocinador / Colaboradores

Localizaciones

Suscribir